WEBULL
WebtradeDownload

Ultragenyx Pharmaceutical (RARE) After FDA Approval, Is The Gene Therapy Win Already Priced In?

Simply Wall St · 3d ago

Ultragenyx Pharmaceutical (RARE) stock is in focus after the U.S. Food and Drug Administration granted accelerated approval for GENGLYCOS, the company’s first gene therapy and a new treatment option for glycogen storage disease type Ia.

At a share price of $25.81, Ultragenyx Pharmaceutical has a 90 day share price return of 15.17%, while the 1 year total shareholder return has declined 19.42%. Recent GENGLYCOS news appears to be improving momentum after several years of weaker overall returns.

Spot other under-the-radar healthcare and biotech stories gaining traction by scanning our hand picked 19 high quality undiscovered gems alongside Ultragenyx Pharmaceutical's latest gene therapy milestone.

Ultragenyx Pharmaceutical shares trade well below the average analyst price target even after the GENGLYCOS approval bounce. Is this a clear discount to fair value, or a sign that the market remains cautious for good reason?

Most Popular Narrative: 70% Undervalued

The most followed narrative values Ultragenyx Pharmaceutical at $26 per share, which is close to the recent $25.81 close. Yet the narrative still frames the stock as significantly undervalued and ties that view to how the business model scales.

The "Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.

Here is why the market is mispricing the friction inside RARE’s operational engine:

Read the complete narrative.

Want to know what turns today’s losses into that fair value estimate? The narrative leans on rapid revenue expansion, improving margins and a future earnings multiple that assumes real operating leverage. Curious which specific growth and profitability assumptions need to hold for Ultragenyx Pharmaceutical to reach that price target?

Result: Fair Value of $26 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Ultragenyx Pharmaceutical still faces two key swing factors: GENGLYCOS uptake versus manufacturing complexity, and whether ongoing restructuring actually reduces the US$586 million annual net loss.

Find out about the key risks to this Ultragenyx Pharmaceutical narrative.

Next Steps

With both risks and rewards in play for Ultragenyx Pharmaceutical, do you want to rely on others or test the thesis yourself? Move quickly, review the data and weigh up the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Ultragenyx Pharmaceutical?

If you stop with Ultragenyx Pharmaceutical, you may miss other stocks that fit your style. Use the Simply Wall St Screener to surface ideas that match your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.